<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Therapeutic options in psoriatic juvenile idiopathic arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Therapeutic options in psoriatic juvenile idiopathic arthritis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Therapeutic options in psoriatic juvenile idiopathic arthritis</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup> <colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Intraarticular glucocorticoids</td> </tr> <tr> <td class="indent1">Triamcinolone hexacetonide</td> <td>0.5 to 1 mg/kg intraarticular, up to 40 mg depending on size of joint. Most effective glucocorticoid for joint injections; not for soft tissue injections.</td> </tr> <tr> <td class="indent1">Methylprednisolone acetate</td> <td>1 mg/kg intraarticular or soft tissue (including dactylitis), up to 80 mg depending upon size of joint or lesion</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Nonsteroidal antiinflammatory drugs (NSAIDs)</td> </tr> <tr> <td class="indent1">Naproxen</td> <td>5 to 10 mg/kg/dose orally twice daily (maximum 1000 mg/day)</td> </tr> <tr> <td class="indent1">Ibuprofen</td> <td>10 mg/kg/dose orally 3 to 4 times daily (maximum 2.4 g/day)</td> </tr> <tr> <td class="indent1">Celecoxib</td> <td> Body weight dosing: <ul class="decimal_heading"> <li>10 to 25 kg – 50 mg orally twice daily</li> <li>&gt;25 kg – 100 mg orally twice daily</li> <li>Adult – 200 mg orally once to twice daily</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Disease-modifying antirheumatic drugs</td> </tr> <tr> <td class="indent1">Methotrexate*</td> <td>10 to 15 mg/m<sup>2</sup> per week or 0.5 to 1 mg/kg/week (maximum 25 mg per week) administered orally* or subcutaneously with folic acid 1 mg daily or leucovorin calcium</td> </tr> <tr> <td class="indent1">Sulfasalazine</td> <td>15 to 30 mg/kg/dose orally twice daily (maximum 3 g/day)</td> </tr> <tr> <td class="indent1">Leflunomide</td> <td>Body weight dosing: <ul class="decimal_heading"> <li>&lt;20 kg – 10 mg orally every other day</li> <li>20 to 40 kg – 10 mg orally daily</li> <li>&gt;40 kg – 20 mg orally daily</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2">Third-line agents in uveitis</td> </tr> <tr> <td class="indent2">Mycophenolate mofetil<sup>¶</sup></td> <td>12 to 18 mg/kg or 600 mg/m<sup>2</sup> orally twice per day (maximum 3 g/day)<sup>¶</sup></td> </tr> <tr> <td class="indent2">Cyclosporine (microemulsion)</td> <td>1.5 to 2.5 mg/kg orally twice per day</td> </tr> <tr> <td class="indent2">Azathioprine</td> <td>1 to 2 mg/kg orally once per day or in 2 equal divided doses</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Tumor necrosis factor (TNF) inhibitors</td> </tr> <tr> <td class="indent1">Adalimumab</td> <td>Body weight dosing: <ul class="decimal_heading"> <li>15 to 30 kg – 20 mg subcutaneously every 2 weeks</li> <li>≥30 kg – 40 mg subcutaneously every 2 weeks (may escalate to weekly for partial response)</li> </ul> </td> </tr> <tr> <td class="indent1">Etanercept</td> <td>0.8 mg/kg (maximum 50 mg) subcutaneously weekly</td> </tr> <tr> <td class="indent1">Infliximab</td> <td>5 to 10 mg/kg intravenously every 4 to 8 weeks (after loading doses)</td> </tr> <tr> <td class="indent1">Golimumab</td> <td> Intravenous: <ul class="decimal_heading"> <li>Children ≥2 years – 80 mg/m<sup>2</sup> weeks 0 and 4, then every 8 weeks (maximum dose 240 mg)</li> <li>Adults – 2 mg/kg weeks 0 and 4, then every 8 weeks (no defined maximum dose)</li> </ul> <p class="extra_spacing_top">Subcutaneous (no pediatric indication) – 50 mg monthly</p> </td> </tr> <tr> <td class="indent1">Certolizumab (no pediatric indication) </td> <td>200 mg subcutaneously every 2 weeks (after loading doses)</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Phosphodiesterase 4 (PDE4) inhibitor</td> </tr> <tr> <td class="indent1">Apremilast (no pediatric indication)</td> <td>30 mg twice daily (begin 10 mg daily and increase over 6 days to achieve target dose)</td> </tr> <tr> <td class="subtitle2_left" colspan="2">IL-17 inhibitor (patients ≥2 years)</td> </tr> <tr> <td class="indent1">Secukinumab</td> <td> <p>Subcutaneous injection weeks 0, 1, 2, 3, 4, then every 4 weeks</p> Body weight dosing: <ul class="decimal_heading"> <li>≥15 kg through ≤50 kg – 75 mg/dose</li> <li>≥50 kg – 150 mg/dose</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">IL-12/23 inhibitor (patients ≥6 years)</td> </tr> <tr> <td class="indent1">Ustekinumab</td> <td> <p>Subcutaneous injection weeks 0 and 4, then every 12 weeks</p> Body weight dosing: <ul class="decimal_heading"> <li>&lt;60 kg – 0.75 mg/kg/dose</li> <li>60 to 100 kg – 45 mg/dose</li> <li>&gt;100 kg – 90 mg/dose</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">CTLA4-Ig (T cell costimulatory blocker)</td> </tr> <tr> <td class="indent1">Abatacept</td> <td>10 mg/kg (maximum 1000 mg) intravenously every 4 weeks</td> </tr> </tbody></table></div><div class="graphic_lgnd"><strong>NOTE: Treatment should be performed by clinicians who are experienced in the use, monitoring, adjustment, and drug interactions of these agents because of the potential toxicity of these drugs/combinations and the unpredictability of the disease.</strong></div><div class="graphic_footnotes"><p>* Divided oral dosing or subcutaneous administration is suggested for methotrexate doses &gt;10 mg/m<sup>2</sup> since oral absorption decreases with higher doses.</p>
¶ Mycophenolate mofetil dosing shown is for immediate release oral preparation. Dose adjustment is required for conversion to the delayed-release oral preparation.</div><div id="graphicVersion">Graphic 64063 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
